FAQs: Challenging host cell protein assays for improved risk mitigationFAQs: Challenging host cell protein assays for improved risk mitigation

BPI Contributor

January 22, 2021

1 Min Read
FAQs: Challenging host cell protein assays for improved risk mitigation

Already have an account?


Host cell proteins (HCP) are critical to quality control in biologics development. If left unremoved, they can cause immunogenic responses and reduce drug efficacy.
In our last webinar we shared Cytiva’s strategy for designing a comprehensive HCP risk mitigation strategy. We discussed how to challenge your assays early to ensure accurate measurements, build confidence, and reduce the risk of unexpected HCP levels.

Our HCP experts highlighted and responded to the most common questions raised around host cell protein assays. Want insight on the challenges scientists are facing today? Fill out the form below to access your download.



Subscribe to receive our monthly print or digital publication
Join our 70,000+ readers. And yes, it's completely free.

You May Also Like